New hope for advanced liver cancer patients in groundbreaking immunotherapy trial

NCT ID NCT01658878

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested new immunotherapy drugs (nivolumab alone and combined with ipilimumab) for people with advanced liver cancer that could not be treated with surgery. It aimed to find safe doses and see if these drugs could shrink tumors and help patients live longer. The trial included 657 adults, some with and some without hepatitis B or C infection, and compared the new drugs to an older standard treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Portland, Oregon, 97213, United States
Local Institution - 0002

Ann Arbor, Michigan, 48109-5331, United States
Local Institution - 0003

Pamplona, 31008, Spain
Local Institution - 0005

Hong Kong, 0, Hong Kong
Local Institution - 0006

Hong Kong, Hong Kong
Local Institution - 0007

Singapore, 308433, Singapore
Local Institution - 0008

Los Angeles, California, 90033, United States
Local Institution - 0009

Singapore, 168583, Singapore
Local Institution - 0010

London, NW3 2QG, United Kingdom
Local Institution - 0011

London, Greater London, SE19RT, United Kingdom
Local Institution - 0012

Glasgow, Lanarkshire, G12 0YN, United Kingdom
Local Institution - 0013

Birmingham, West Midlands, B15 2TH, United Kingdom
Local Institution - 0014

Manchester, Greater Manchester, M20 4BX, United Kingdom
Local Institution - 0015

Metropolitan Borough of Wirral, Merseyside, CH63 4JY, United Kingdom
Local Institution - 0016

Seoul, 06351, South Korea
Local Institution - 0017

Singapore, 119074, Singapore
Local Institution - 0018

Madrid, 28050, Spain
Local Institution - 0019

Barcelona, 08036, Spain
Local Institution - 0020

Madrid, 28009, Spain
Local Institution - 0021

Seoul, 03080, South Korea
Local Institution - 0022

Montreal, Quebec, H2X 3E4, Canada
Local Institution - 0023

Taoyuan District, 333, Taiwan
Local Institution - 0024

Taipei, 112, Taiwan
Local Institution - 0025

Boston, Massachusetts, 02114, United States
Local Institution - 0026

Seoul, 05505, South Korea
Local Institution - 0027

Taipei, 100, Taiwan
Local Institution - 0028

Frankfurt, 60590, Germany
Local Institution - 0029

Hanover, 30625, Germany
Local Institution - 0030

Essen, 45147, Germany
Local Institution - 0031

Heidelberg, 69120, Germany
Local Institution - 0032

Bologna, 40138, Italy
Local Institution - 0034

Naples, 80131, Italy
Local Institution - 0035

Padua, Padova, Italy
Local Institution - 0036

Kashiwa-shi, Chiba, 2778577, Japan
Local Institution - 0037

Ōsaka-sayama, Osaka, 5898511, Japan
Local Institution - 0038

Kurume-shi, Fukuoka, 8300011, Japan
Local Institution - 0039

Toronto, Ontario, M5G 2M9, Canada
Local Institution - 0040

Rozzano, 20089, Italy
Local Institution - 0042

Paris, 75651, France
Local Institution - 0047

Atlanta, Georgia, 30322, United States
Local Institution - 0048

Washington D.C., District of Columbia, 20007, United States
Local Institution - 0049

Yokohama, Kanagawa, 2320024, Japan
Local Institution - 0050

Kyoto, Kyoto, 6028566, Japan
Local Institution - 0051

Saga, 8408571, Japan
Local Institution - 0053

Pensacola, Florida, 32504, United States
Local Institution - 0054

Hackensack, New Jersey, 07601, United States
Local Institution - 0055

Milan, 20141, Italy
Local Institution - 0056

Florence, 50134, Italy
Local Institution - 0058

Vandœuvre-lès-Nancy, 54500, France
Local Institution - 0059

Marseille, 13385, France
Local Institution - 0060

Reims, 51092, France
Local Institution - 0061

Angers, 49933, France
Local Institution - 0062

Marseille, 13273, France
Local Institution - 0063

Meldola (FC), 47014, Italy
Local Institution - 0064

Créteil, 94010, France
Local Institution - 0065

Halifax, Nova Scotia, B4H 2Y9, Canada
Local Institution - 0066

Seoul, 02841, South Korea
Local Institution - 0067

Paterson, New Jersey, 07503, United States
Local Institution - 0070

San Juan, 00927, Puerto Rico
The University Of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CARCINOMA